Unresectable Locally Advanced Or Metastatic Hepatocellular Carcinoma
ADAGAdagene IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Muzastotug (ADG126) (Masked CTLA-4 Antibody) in Unresectable Locally Advanced Or Metastatic Hepatocellular Carcinoma. The expected timing is based on the latest available company guidance and may change.
03/17/26:- Results from Ph1b/2 Morpheus Liver muzastotug combo arm to be presented at AACR Apr 20, 2026. 04/17/26:- MORPHEUS-Liver (NCT04524871) Ph1b/2 triplet ORR 66.7% vs 32.5%; safety comparable. 08/12/26:- Reiterated MORPHEUS-Liver NCT04524871 Ph1b/2 triplet data showed 66.7% response rate and comparable safety.
Verification
Confirm timing and program details against the company announcement or filing.